What Custom Pharmaceutical Intermediate Capability Actually Looks Like: Key Verification Points

When buyers evaluate a pharmaceutical intermediate manufacturer, the first documents they usually check are the product specification, purity data and price list. But for projects moving from evaluation into execution, the more important question is capability: can this supplier meet your custom structural requirements, adjust purity and specification, support a specific process route, and deliver stable quality when you move from grams to hundreds of kilograms?

This guide explains what custom pharmaceutical intermediate capability really involves, using Haohong (Qihe) Pharmaceutical Technology Co., Ltd. as a practical example. Haohong is a manufacturer based in the High-tech Zone of Qihe County, Dezhou City, Shandong Province, China. The company specializes in R&D and custom production of innovative active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, with a focus on high-grade intermediates for anti-cancer, anti-hepatitis C and anti-diabetic therapies.

Why Capability Is the Missing Piece in Supplier Evaluation

A product that looks acceptable on paper may fail during scale-up if the manufacturer cannot adapt the process, control impurities at commercial scale, or adjust batch size to your project timeline. Buyers often assume that a supplier with a catalog item can also handle custom synthesis. That is not always true. Customization requires analytical resources, production flexibility, and a quality system designed to handle changes without losing batch-to-batch consistency.

The risk is visible in every stage: a wrong process route increases expensive rework; inconsistent purity creates regulatory delays; rigid MOQ and lead times slow down development programs. Therefore, the evaluation should be based on verified supplier capabilities, not just product photographs or certificates.

Market Context: Why Custom and High-Purity Intermediates Matter

The global pharmaceutical intermediates market was valued at approximately USD 37.04 billion in 2025, according to Precedence Research. Generic drug manufacturers held a dominant 53.82% share of the market in 2024, while North America accounted for 42.23% of market value, according to Mordor Intelligence and BioSpace. China’s pharmaceutical industry total exports reached USD 22.53 billion as of December 2024, based on CEIC/OECD data.

Within this market, oncology drug intermediates generated 37.20% of total industry revenue in 2025, driven in part by complex antibody-drug conjugates, according to Grand View Research. Peptide and oligonucleotide intermediates are projected to be the fastest-growing segment, with an estimated 8.12% CAGR through 2030, based on Mordor Intelligence data. For buyers, this means demand is shifting toward specialized, high-purity, custom-synthesized intermediates rather than simple commodity chemicals.

Regulatory expectations reinforce this trend. The FDA’s ICH Q7 guidance provides the primary Good Manufacturing Practice (GMP) framework for APIs and their intermediates. In the European Union, pharmaceutical intermediates imported in volumes above 1 tonne per year must comply with REACH registration, even though APIs may be exempt. Together, these market and regulatory factors make capability assessment a core procurement task.

What a Complete Custom Pharmaceutical Intermediate Capability Looks Like

Haohong Pharmaceutical provides a practical example of a customized service model. It offers technical support covering structural customization, purity and specification customization, process route customization, capacity and batch customization, packaging and standard customization, and R&D and OEM/ODM customization. For buyers, this means the supplier can engage at different points of the development chain: from early route design to commercial batch production.

Behind these service options is a production base in Liaocheng equipped with 30 sets of 3,000–5,000L reactors, with an annual production capacity of 1,000 tons. The R&D team includes 30 engineers. The company also passed ISO 9001:2015 quality management system certification in 2021 and was recognized as a Technology-based Small and Medium-sized Enterprise in 2024 and an Innovative Small and Medium-sized Enterprise of Shandong Province in 2025.

For ongoing operations, the company reports a monthly production capacity of 100 metric tons across relevant product lines. Minimum order quantity and production lead time are tailored to each customer rather than fixed. This kind of flexibility matters when a development program changes volume requirements between phases.

Customization Types at a Glance

ODM production services are available for markets including the United States, Europe, India and Bangladesh. Haohong’s export services cover the United States, Europe, India, Bangladesh and other regions, with an export ratio of approximately 40%.

Quality Control: The Backbone of Capability

Custom capability is only meaningful when supported by quality control. Haohong’s quality control system includes seven core checks:

1. Appearance and property inspection
2. Core chromatographic testing (HPLC/GC)
3. Structural qualitative identification
4. Physical and chemical index testing
5. Heavy metal and impurity testing
6. Microbiological testing
7. Factory delivery supporting documents

In addition, the company holds utility model patents registered with the China National Intellectual Property Administration. These cover production equipment for pharmaceutical intermediates, including a waste gas absorption device, a powder refining and mixing device, and a gas chromatography device for detecting pharmaceutical intermediates. The patents reflect attention to both product quality and production environment control.

Use Case: How Custom Intermediates Perform in Finished Medicine Projects

In a documented project for a top-tier pharmaceutical group, Haohong’s intermediates were used as starting materials synthesized and processed into final finished medicines. The typical duration for the supplied materials under specified storage conditions was 12–24 months. The project demonstrated several outcomes that matter to buyers:

• High reaction yield, reducing the production cost of finished pharmaceuticals
• Low levels of impurities, heavy metals and residual solvents, minimizing drug safety risks
• Stable batch-to-batch quality, improving consistency in pharmaceutical production
• Simplified downstream synthesis processes, shortening development cycles
• Accelerated drug registration processes

These outcomes align with Haohong’s focus on active pharmaceutical ingredients and intermediates for anti-cancer, anti-hepatitis C and anti-diabetic therapies, with emphasis on high-grade intermediates. Representative product families include Apalutamide intermediates, Abemaciclib intermediates and Alectinib intermediates, with typical purity of ≥98% by HPLC or GC.

Step-by-Step: How to Verify Custom Pharmaceutical Intermediate Capability

Use the following seven-step framework when moving from evaluation to execution with a potential supplier.

Step 1: Define the Required Customization Type

Before sending an inquiry, identify which dimension is most critical: molecular structure, purity/specification, process route, capacity, packaging or full ODM development. This determines which questions to ask and which evidence to request.

Step 2: Verify the Quality Management System

Check whether the supplier holds a recognized quality certificate. Haohong has passed ISO 9001:2015, certificate number 174Q240545R0S, issued by Shandong Guojian Certification Co., Ltd. in November 2024 and valid until November 2027.

Step 3: Assess Analytical and Testing Capability

A capable manufacturer should be able to perform chromatographic testing, structural identification, physical and chemical index testing, heavy metal and impurity testing, and microbiological testing. Ask how the laboratory documents these results.

Step 4: Review Process and Equipment Patents

Patents can indicate a supplier’s attention to production equipment and process improvement. Haohong’s utility model patents cover production equipment, waste gas absorption and powder refining/mixing, which support cleaner and more consistent manufacturing.

Step 5: Evaluate Capacity and Scale-Up Flexibility

Check whether the supplier can handle both small-scale development and commercial production. Haohong’s Liaocheng production base uses 30 reactors in the 3,000–5,000L range, with monthly capacity around 100 MT for relevant product lines.

Step 6: Confirm MOQ, Lead Time and Commercial Terms

For custom work, MOQ and lead time are often flexible. Haohong treats both as tailor-made services. Commercial terms include EXW, FOB, CFR, CIF, air freight, international express, and DDP/DDU door-to-door delivery; payment is typically 50/50.

Step 7: Request a Pre-shipment Test or Small-Batch Sample

Before full execution, require a pre-shipment test or sample re-inspection. Haohong supports pre-shipment testing, sample re-inspection and third-party testing as part of its after-sales process.

Capability Comparison Table: What to Verify vs. What Haohong Provides

Frequently Asked Questions

Conclusion

Custom pharmaceutical intermediate capability is not a single feature; it is a combination of customization depth, quality control, production flexibility, commercial terms and proof from real projects. Buyers who verify these dimensions before scale-up reduce the risk of batch failure, regulatory delay and cost overrun.

Haohong Pharmaceutical provides a useful reference: ISO 9001:2015 certification, multi-dimensional customization services, a documented quality control system, scalable production capacity and flexible commercial terms. When you evaluate a supplier, ask for evidence rather than assumptions. Then run a small-batch test or request pre-shipment inspection before committing to full execution.